Cargando…
The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile
The EMPA-REG OUTCOME (Empagliflozin, Cardiovascular Outcome Event Trial in patients with Type 2 Diabetes Mellitus (T2DM)) trial evidenced the potential of sodium-glucose cotransporter 2 (SGLT2) inhibitors for the treatment of patients with diabetes and cardiovascular disease. Recent evidences have s...
Autores principales: | Aragón-Herrera, Alana, Otero-Santiago, Manuel, Anido-Varela, Laura, Moraña-Fernández, Sandra, Campos-Toimil, Manuel, García-Caballero, Tomás, Barral, Luis, Tarazón, Estefanía, Roselló-Lletí, Esther, Portolés, Manuel, Gualillo, Oreste, Moscoso, Isabel, Lage, Ricardo, González-Juanatey, José Ramón, Feijóo-Bandín, Sandra, Lago, Francisca |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847595/ https://www.ncbi.nlm.nih.gov/pubmed/35185578 http://dx.doi.org/10.3389/fphar.2022.827033 |
Ejemplares similares
-
Adipokines and Inflammation: Focus on Cardiovascular Diseases
por: Feijóo-Bandín, Sandra, et al.
Publicado: (2020) -
Relaxin-2 as a Potential Biomarker in Cardiovascular Diseases
por: Aragón-Herrera, Alana, et al.
Publicado: (2022) -
Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models
por: Feijóo-Bandín, Sandra, et al.
Publicado: (2022) -
Relaxin-2 plasma levels in atrial fibrillation are linked to inflammation and oxidative stress markers
por: Aragón-Herrera, Alana, et al.
Publicado: (2022) -
Relaxin-2 in Cardiometabolic Diseases: Mechanisms of Action and Future Perspectives
por: Feijóo-Bandín, Sandra, et al.
Publicado: (2017)